SG Capital Management LLC bought a new position in shares of Cutera, Inc. (NASDAQ:CUTR) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 80,597 shares of the medical device company’s stock, valued at approximately $1,675,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Cutera by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 146,623 shares of the medical device company’s stock valued at $2,495,000 after acquiring an additional 7,013 shares during the last quarter. Gabelli Funds LLC lifted its position in Cutera by 5.6% during the 1st quarter. Gabelli Funds LLC now owns 644,807 shares of the medical device company’s stock worth $11,387,000 after acquiring an additional 34,400 shares during the period. Stephens Inc. AR acquired a new stake in Cutera during the 1st quarter worth approximately $276,000. Two Sigma Advisers LP lifted its position in Cutera by 2.5% during the 4th quarter. Two Sigma Advisers LP now owns 55,827 shares of the medical device company’s stock worth $950,000 after acquiring an additional 1,357 shares during the period. Finally, Legal & General Group Plc lifted its position in Cutera by 3.2% during the 4th quarter. Legal & General Group Plc now owns 29,967 shares of the medical device company’s stock worth $506,000 after acquiring an additional 942 shares during the period. Institutional investors own 92.47% of the company’s stock.
Shares of CUTR traded down $0.43 during mid-day trading on Thursday, hitting $25.13. The company’s stock had a trading volume of 2,670 shares, compared to its average volume of 95,362. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.66 and a quick ratio of 1.09. The business has a 50-day moving average of $21.83. The stock has a market capitalization of $358.86 million, a price-to-earnings ratio of -11.32 and a beta of 0.88. Cutera, Inc. has a 1-year low of $12.32 and a 1-year high of $41.50.
CUTR has been the subject of a number of recent research reports. Zacks Investment Research raised Cutera from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. BidaskClub raised Cutera from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, ValuEngine raised Cutera from a “hold” rating to a “buy” rating in a research report on Friday, July 12th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $34.67.
In other Cutera news, Director J Daniel Plants purchased 28,166 shares of Cutera stock in a transaction dated Monday, June 3rd. The stock was acquired at an average cost of $16.73 per share, with a total value of $471,217.18. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders bought a total of 49,522 shares of company stock valued at $832,825 over the last three months. Insiders own 2.30% of the company’s stock.
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Featured Article: Risk Tolerance
Want to see what other hedge funds are holding CUTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cutera, Inc. (NASDAQ:CUTR).
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.